FGSI - ETF AI Analysis
Top Page
FT Vest Growth Strength & Target Income ETF (FGSI)
The ETF FGSI reflects a solid overall rating, driven by strong contributions from holdings like Incyte (INCY) and TJX Companies (TJX). Incyte stands out with its robust profitability, strategic R&D investments, and bullish momentum, while TJX benefits from strong revenue growth, raised guidance, and effective cost management. However, some holdings, such as Eli Lilly (LLY), face challenges like high leverage and declining cash flow, which may slightly weigh on the fund's overall performance. A key risk factor is the ETF's broad exposure to stocks with valuation concerns, which could impact future returns.
FGSI vs. SPDR S&P 500 ETF (SPY)
- AUM
- 2.03M
- Region
- North America
- Expense Ratio
- 0.85%
- Beta
- 0.84
- Issuer
- FT Vest
- Inception Date
- Jun 26, 2025
- Dividend Yield
- 8.50%
- Asset Class
- Alternatives
- Index Tracked
- No Underlying Index
FGSI Summary
The FT Vest Growth Strength & Target Income ETF (FGSI) is designed for investors who want both growth and income. It focuses on strong U.S. companies, including well-known names like Netflix and Broadcom, and invests in dividend-paying stocks across sectors like technology, financials, and healthcare. FGSI uses a unique strategy to boost income by writing options, aiming for a yield higher than the average S&P 500 dividend rate. This ETF could be a good choice for those seeking diversification and steady income. However, new investors should know that its performance depends heavily on the U.S. market and sectors like technology, which can be volatile.
How much will it cost me?
The FT Vest Growth Strength & Target Income ETF (FGSI) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it’s actively managed, using strategies like S&P 500 call-writing to enhance returns and income potential.
What would affect this ETF?
FGSI’s focus on U.S. dividend-paying stocks and its active call-writing strategy could benefit from a stable or growing economy, particularly if technology and financial sectors continue to perform well. However, rising interest rates or regulatory changes affecting options strategies might negatively impact its income generation and overall returns. Additionally, sector-specific challenges, such as volatility in technology or healthcare, could pose risks to its top holdings.
FGSI Top 10 Holdings
The FGSI ETF leans heavily into technology, with over a third of its portfolio in the sector, making it a key driver of performance. Amphenol is a standout, rising steadily thanks to strong financial results and bullish sentiment, while Eli Lilly and United Therapeutics add momentum with their robust growth and strategic initiatives in healthcare. However, Apollo Global Management is lagging, weighed down by mixed signals and valuation concerns, and Schlumberger’s struggles in cash flow are holding back energy sector contributions. Overall, the fund’s U.S.-focused, growth-oriented strategy is delivering mixed results, with tech and healthcare leading the charge.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 2.15% | $43.96K | $1.33T | 67.86% | 71Outperform |
 INCY | Incyte | 2.02% | $41.35K | $24.54B | 30.02% | 81Outperform |
 AVGO | Broadcom | 2.05% | $42.09K | $1.56T | -13.38% | 76Outperform |
 UTHR | United Therapeutics | 2.17% | $44.52K | $25.68B | 32.01% | 79Outperform |
 APH | Amphenol | 2.02% | $41.37K | $195.55B | 14.01% | 77Outperform |
 BKR | Baker Hughes Company | 1.91% | $39.14K | $54.85B | 13.69% | 78Outperform |
 SLB | Schlumberger | ― | ― | ― | ― | 75Outperform |
 CAT | Caterpillar | ― | ― | ― | ― | 76Outperform |
 CBOE | Cboe Global Markets | ― | ― | ― | ― | 75Outperform |
 APO | Apollo Global Management | ― | ― | ― | ― | 75Outperform |
FGSI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FGSI, the sentiment is Negative. The current price of 19.91 is below the 20-day moving average (MA) of 20.27, below the 50-day MA of 20.31, and above the 200-day MA of 19.62, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 40.47 is Neutral, neither overbought nor oversold. The STOCH value of 43.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FGSI.
FGSI Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FGSI | $19.92 | $21.50(7.96% Upside) | $2.03M | 0.85% | 72Outperform |
 GROZ | $32.17 | $42.04(30.69% Upside) | $124.01M | 0.55% | 75Outperform |
 HGRO | $29.42 | $33.65(14.39% Upside) | $108.48M | 0.70% | 70Neutral |
 AOTG | $59.23 | $87.84(48.29% Upside) | $103.12M | 0.75% | 71Outperform |
 SEMG | $27.25 | $34.45(26.41% Upside) | $63.84M | 0.60% | 72Outperform |
 RILA | $12.15 | $15.15(24.73% Upside) | $45.10M | 0.50% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FGSI | FT Vest Growth Strength & Target Income ETF | 19.91 | 1.03 | 5.48% | |
| GROZ | Zacks Focus Growth ETF | 32.16 | 1.51 | 4.93% | |
| HGRO | Hedgeye Quality Growth ETF | 29.42 | 0.95 | 3.35% | |
| AOTG | AOT Growth and Innovation ETF | 59.23 | 0.14 | 0.23% | |
| SEMG | Suncoast Select Growth ETF | 27.25 | 0.12 | 0.46% | |
| RILA | Indexperts Gorilla Aggressive Growth ETF | 12.15 | 0.18 | 1.47% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.